Mydriatics: Drop the dose by Hendricks, Jerry A et al.
Pacific University 
CommonKnowledge 
College of Optometry Theses, Dissertations and Capstone Projects 
4-1997 
Mydriatics: Drop the dose 
Jerry A. Hendricks 
Pacific University 
Tracy E. Dodd 
Pacific University 
Craig F. Rouse 
Pacific University 
Recommended Citation 
Hendricks, Jerry A.; Dodd, Tracy E.; and Rouse, Craig F., "Mydriatics: Drop the dose" (1997). College of 
Optometry. 1201. 
https://commons.pacificu.edu/opt/1201 
This Thesis is brought to you for free and open access by the Theses, Dissertations and Capstone Projects at 
CommonKnowledge. It has been accepted for inclusion in College of Optometry by an authorized administrator of 
CommonKnowledge. For more information, please contact CommonKnowledge@pacificu.edu. 
Mydriatics: Drop the dose 
Abstract 
This study investigated the difference in pupillary dilation between a normal dose and a substandard dose 
of a topical ophthalmic mydriatic agent, the combination of hydroxyamphetamine hydrobromide 1% and 
tropicamide 0.25% (Paremyd™ solution). The manufacturer's recommended dosage is 1-2 drops per eye. 
A typical opthalmic drop ranges in volume from 30 - 75. We hypothesized that a small, substandard dose 
of 10 will create a pupillary dilation clinically and statistically equivalent to that of the larger, standard 
dose of 30 in part due to the reflex tear response and increased lacrimal drainage. Our research found 
that the smaller dose of the mydriatic does indeed provide a clinically and statistically equivalent pupillary 
dilation to the larger dose. Clinically, the use of a reduced dose of a topical mydriatic will reduce the 
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ABSTRACT: 
This study investigated the difference in pupillary dilation between a 
normal dose and a substandard dose of a topical ophthalmic mydriatic agent, 
the combination of hydroxyamphetamine hydrobromide 1% and tropicamide 
0.25% (Paremyd™ solution). The manufacturer's recommended dosage is 1-2 
drops per eye. A typical opthalmic drop ranges in volume from 30 - 75 ~L. 
We hypothesized that a small, substandard dose of 10 ~L will create a 
pupillary dilation clinically and statistically equivalent to that of the 
larger, standard dose of 30 ~L. in part due to the reflex tear response and 
increased lacrimal drainage. Our research found that the smaller dose of the 
mydriatic does indeed provide a clinically and statistically equivalent 
pupillary dilation to the larger dose. Clinically, the use of a reduced dose of 
a topical mydriatic will reduce the inherent risks and side effects to the 
patient (especially to the high-risk patient), while still allowing the eye 
care practitioner ample pupillary dilation to provide a quality dilated fundus 
examination. 
KEYWORDS: 
mydriasis; mydriatic; dilation; drop size; dose; pupil; eyedropper; Paremyd; 
hydroxyamphetamine hydrobromide; tropicamide 
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INTRODUCTION: 
Routine pupillary dilation has become a standard procedure in optometric 
practice, and is necessary for a thorough evaluation of the posterior 
segment of the eye. 1•6 Topical mydriatic medications play a critical role in 
any eye care practitioner's practice. Several risks and side effects must be 
considered when using these medications. Systemic absorption risks may 
include the following: increased ocular pressure, dryness of mouth, blurred 
vision, CNS disturbances, sweating, tachycardia, headache, hypertension, 
myocardial infarction, allergic reactions, nausea, vomiting, palor, 
subarachnoid hemorrhage, cardiac arrhythmias, muscle rigidity, gastric 
secretory dysfunction, necrotizing entercolitis, and death.5 '7.11 Patient 
discomfort (e.g., transient stinging and photophobia) resulting from the use 
of these drops is a factor as well.8 '12 One way of decreasing these risks and 
side effects is to decrease the drop volume instilled into the patients' eyes. 
Normal fluid holding capacity of the tear film is approximately 7 to 10 J.ll 
with a maximum expandable volume of 30 J.ll before blinking.13•16 Any excess 
fluid (tears and/or drops) is quickly blinked out onto the cheek or into the 
nasolacrimal drainage system to restore the tears to its normal volume. 
Systemic absorption takes place via the vascularized mucous membrane of 
the nasolacrimal system. A smaller drop volume would reduce the amount of 
fluid forced into the nasolacrimal ducts, thereby reducing the systemic 
uptake of medications into the circulatory system. This systemic uptake 
reduction inherently reduces the possibility and magnitude of adverse 
systemic side effects and toxicities. 
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Another aspect of concern is the reflex tearing associated with instillation 
of ophthalmic drops. Irritating or hypertonic solutions instilled into the eye 
result in a more rapid tear dilution (due to hypersecretion of tears) and thus 
a lower concentration and quantity of drug remains in the tear film. 14 A 
smaller drop size will potentially produce less ocular irritation to the 
patient, thus resulting in decreased reflex tearing, less lacrimal washout, 
increased drug-corneal contact time, and improved patient comfort. 
A number of researchers have previously investigated the effects of 
reducing mydriatic drop volumes. Gray found that equivalent mydriasis was 
achieved with 5 ~-tL of tropicamide 1% as compared to a 26 ~-tL dose.12 Brown 
eta/. found that a better dilation was achieved with an 8 ~-tL drop of 
phenylephrine 10% than with a 32 ~-tL drop of phenylephrine hydrochloride 
2.5%.10 Lynch eta/. showed that 8 ~-tL of phenylephrine 2.5% dilates as well 
as 30 ~-tL, while systemic absorption dropped by 50%. 9 Wheatcroft et a/. 
found that 5 ~-tL of cyclopentolate 0.5% and phenylephrine 2.5% produced 
equivalent dilation in premature infants compared to a 26 ~-tL dose.17 Craig 
and Griffiths demonstrated a 10 ~-tL drop of phenylephrine 10% dilates just 
as well as a standard 30 ~-tL drop.11 
Our study investigated the difference in pupillary dilation between a 30 ~-tL 
dose (a typical mydriatic drop volume) 14' 15'18 and a 10 ~-tL dose of a common 
mydriatic agent. Note that some researchers state that standard 
commercial eyedroppers produce dropsranging in volume from 50-75 
~-tL. 13 • 15• 19 ·20 We chose the combination of hydroxyamphetamine hydrobromide 
1% and tropicamide 0.25% (Paremyd) as our test mydriatic due to its clinical 
efficacy and convenience of a single-bottle administration system. 
Hydroxyamphetamine is an indirect-acting sympathomimetic agent which 
6 
causes the release of norepinephrine from the intact post-ganglionic 
adrenergic nerve terminals, which in turn stimulate the dilator, producing 
mydriasis. Tropicamide is a parasympatholytic agent which blocks the 
sphincter receptor sites, thus producing mydriasis. Because these two 
agents act on different effector sites, their combined application produces 
an additive mydriatic effect greater than either of the singular effects.8 
As stated in the PDR for Ophthalmology, the recommended dosage of Paremyd 
for routine pupillary dilation is one to two drops per eye; it also states that 
the onset of action with Paremyd occurs within 15 minutes, followed by 
maximum effect within one hour.8 
As shown in Table 1, due to the variation in drop size and number of drops 
administered, the amount of drug actually delivered for a routine bilateral 
dilation can be quite variable. This is a considerable difference in drug 
dosage, and is a critical issue when considering systemic absorption. 
Table 1: Potential Drug Quantities Delivered for Bilateral Dilation 
Dosage (Paremyd) Hydroxyamphetamine Tropicamide 
Hydrobromide 
One 1 0 J..LL drop X 2 eyes 0.2 mg 0.05 mg 
One 30 J..LL drop X 2 eyes 0.6 mg 0.15 mg 
Two 75 1-1L drops X 2 eyes 3.0 mg 0.75 mg 
A dilated pupil of at least 7 mm diameter is sufficient to permit a thorough 
examination of the fundus, including the peripheral retina.21 Therefore, for 
the purpose of this experiment, we have defined a "clinically significant 
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pupillary dilation" as one which achieves at least a 7 mm diameter within 
30 minutes post-administration. 
We hypothesized that a substandard dose of a topical mydriatic agent would 
create a pupillary dilation clinically and statistically equivalent to that of 
the larger, standard dose. Clinically, the use of a reduced dose of a topical 
mydriatic will reduce the inherent risks and side effects to the patient 
while still providing a clinically significant pupillary dilation. 
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METHODS: 
Subjects: 
The study compared the mydriatic response of 24 subjects (15 females, 9 
males). Of the selected subject pool, 8 had light-colored irides, 10 had 
medium-colored irides, and 6 had dark irides (these findings based upon 
subjective determination by the researchers). The criterion for selection of 
the subject pool was as follows: 
• Age: 19- 50 years old (mean= 27 years, S.D.= 3.8 years); 
• No known allergies to Paremyd (hydroxyamphetamine hydrobromide 1% + 
tropicamide 0.25%) 
• No history of anterior segment eye disease which permanently affected 
the actions of the iris or ciliary body; 
• No history of hypertension, hyperthyroidism, diabetes, or cardiac disease; 
• No history of retinal disease; 
• No history of anisocoria, Horner's Syndrome, Adie's Pupil, Adie's 
Syndrome, Marcus Gunn afferent pupillary defect, third nerve palsy, or 
other pupillary disorder; 
• Not currently taking any drugs which can cause mydriasis, including 
anticholinergics, CNS stimulants (amphetamines, methylphenidate, 
cocaine), CNS depressants (barbiturates, anti-anxiety agents), 
antihistamines (including over-the-counter), or phenothiazines; 
• Not currently taking any drugs which can cause miosis, including opiates, 
heroin, codeine, morphine, anticholiesterates (neostigmine); 
• No difficulties in maintaining a steady gaze; 
• No current anisocoria of greater than 1 mm difference (under illuminance 
of 90 ± 5 lux) 
• No history of any neurological disorders or seizures; 
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• No history of glaucoma (including angle-closure glaucoma); 
• No history of subluxated crystalline lens; 
• No history of permanent eye damage due to trauma, disease, or congenital 
conditions; 
• No history of eye surgery; 
• Not currently pregnant or nursing; 
• Non-heterochromia iridium; 
• Anterior chamber angles of grade 3 or 4, as determined by the van Herick 
slit-:lamp technique;22 
• Current lOP's of> 8 and < 21 mm Hg OU (as determined by non-contact 
tonometry); 
• Habitual distance Snellen visual acuities of 20/40 or better (00, OS). 
Apparatus: 
Pupil measurements were obtained using an Essilor corneal reflection 
digital pupillometer. llliminance levels were measured using a Tektronix J-
16 photometer. An adjustable Oxford 3000 micropipette (capacity: 10-50 
~L) with sterile, disposable tips was used to accurately administer the 
topical ophthalmic pharmaceutical agent. The mydriatic agent used was the 
combination of hydroxyamphetamine hydrobromide 1% and tropicamide 0.25% 
(AIIergan's Paremyd™ Solution). 
Preliminary Examination Procedures: 
Every subject was asked to complete an informed consent form and a 
qualification questionnaire before any testing occurred. Each testing 
session started with a preliminary examination consisting of distance 
visual acuities (habitual), non-contact tonometry, pupils evaluation, and a 
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slit-lamp examination (including van Herick assessment of the medial and 
lateral anterior chamber angles). If the subject was a contact lens wearer, 
s/he would be instructed to remove their lenses immediately following the 
determination of their habitual visual acuities. The sessions were held in an 
examination lane with controlled lighting conditions; the room illuminance 
levels were maintained at 90 ± 5 lux, 23 using the light meter and a rheostat 
as control devices. 
Testing Sessions: 
Before the mydriatic solution was administered, the subject's baseline pupil 
diameters was measured using the pupillometer. To accomplish this, the 
subject would be instructed to look at the target inside the pupillometer. 
The researcher would line up the measuring line inside the pupillometer 
with the temporal limit of the right pupil margin, another researcher would 
read and document the digital readout from the meter (in millimeters). 
Next, without having moved the pupillometer since the original reading (i.e., 
it was still on the subject's face), the first researcher would realign the 
mark with the nasal limit of the right pupil margin, and again the data would 
be read and documented. The difference between the two readings was 
recorded as the pupil diameter in millimeters. This process was repeated 
for the left eye. 
Next, the subject would be instructed to tilt their head back slightly and to 
look up and back. A researcher would gently pull the lower right lid out 
slightly so that a trough is formed by the inferior cul-de-sac. The 
researcher would administer 30 J.!L of the combination of 
hydroxyamphetamine hydrobromide 1% and tropicamide 0.25% to the exposed 
cul-de-sac via the micropipette. Another researcher would start the 
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stopwatch at the moment the right eye was administered the drop. The 
subject was instructed to keep their eyes closed for one minute and the 
researcher would occlude the subject's upper and lower right puncta by 
gently pinching the medial canthal area during the course of that minute 
(thereby minimizing lacrimal drainage). After one minute, 10 J.ll of the 
mydriatic solution would be administered to the left eye, the subject was 
instructed to keep both eyes closed for an additional two minutes, and the 
researcher would occlude the subject's upper and lower left puncta in the 
same manner (for the first minute). Note that the right eyes (herein 
referred to as the "30 J.ll eyes") always received the 30 J.ll drops, whereas 
the left eyes (herein referred to as the "10 ~-tL eyes") always received the 10 
~-tl drops. 
After 6 minutes (following application of the mydriatic to the right eye), 
the right pupil diameter was measured and recorded following the same 
methods used previously. One minute later (6 minutes post-left eye 
mydriatic instillation), the left pupil diameter was measured and recorded. 
Subsequent pupil diameter measurements were taken and recorded again 
every 6 minutes up to the 30 minute mark, for a total of five post-
instillation recordings per eye (i.e., at 6, 12, 18, 24, and 30 minutes post-
instillation per eye). 
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RESULTS: 
Four different methods of analysis were used: 
• whether or not the dilation was "clinically significant", 
• maximum pupil diameter increase (".1 Diameter'), 
• maximum pupil area increase (".1 Area"), 
• time to maximum dilation. 
Note that all measurements were taken within a 30 minute time frame. 
Reference Table 2. 
Table 2: Summary of Dilation Responses 
Criterion 10 J-LL eye 30 J-LL eye 
(within 30 minutes) (OS) (00) 
%of eyes tested achieving 
mydriasis of '27 mm 100% 100% 
diameter 
.1 Diameter (mm) Mean= 1.81 Mean= 1.94 
S.D.= 0.94 S.D.= 0.79 
.1 Area (mm2) Mean= 19.48 Mean= 20.84 
S.D.= 9.76 S.D.= 7.71 
Time to maximum dilation Mean= 24.00 Mean= 23.25 
(minutes) S.D.= 7.30 S.D.= 6.46 
Within the 30 minute time frame, all of our subjects achieved a dilation of 
at least a 7 mm diameter in both the 1 0 J-LL eyes and the 30 J-LL eyes. 
Therefore, based upon the pre-established criterion defining a "clinically 
significant dilation" as '27 mm overall pupil diameter, 100% of all eyes 
tested successfully obtained a clinically significant dilation within 30 
minutes. 
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The mean .1 Diameter for the 30 1-1L eyes was 1.94 mm, whereas the mean .1 
Diameter for the 10 1-1L eyes was 1.81 mm. Probability was 35.4%, showing 
there is no statistically significant difference between these means (using 
a repeated measures two-tailed t-test with rejection critical value of 5%). 
Assuming that the pupils measures were perfectly circular before and after 
dilation, the mean .1 Area for the 30 1-1L eyes was 20.84 mm2, whereas the 
mean .1 Area for the 10 1-1L eyes was 19.48 mm2. Probability was 36.9%, 
showing there is no statistically significant difference between these 
means (using a repeated measures two-tailed t-test with rejection critical 
value of 5%). 
Mean time to maximum dilation within 30 minutes for the 30 1-1L eyes was 
23.25 minutes, whereas the mean time for the 10 1-1L eyes was 24.00 
minutes. Once again, these means show no statistically significant 
difference. 
As shown in Table 3, there was little variation between the 10 1-1L and the 
30 1-1L eyes within any given irides darkness category (i.e., light, medium, 
dark) for either~ Diameter,~ Area, or time to maximum dilation. However, 
there was (dosage independent) variation in~ Diameter and ~Area due to 
irides darkness, presumably due to pigment absorption of the drug. 
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Table 3: Means of Dilation Responses by Irides Darkness 
Irides 10 J.ll eye 30 J.ll eye 
Darkness (OS) (OD) 
.1 Diameter ! Overall Mean=1.81 Mean=1.94 (mm} S.D.= 0.94 S.D.= 0.79 
Light Mean=2.19 Mean=2.38 
S.D.= 0.92 S.D.= 0.83 
Medium Mean=1.70 Mean=1.85 
S.D.= 1.01 S.D.= 0.71 
Dark Mean=1.50 Mean=1.50 
S.D.= 0.84 S.D.= 0.63 
.1 Area Overall Mean=19.48 Mean=20.84 
(mm2) S.D.= 9.76 S.D.= 7.71 
Light Mean=22.46 Mean=24.45 
S.D.= 9.15 S.D.= 8.21 
Medium Mean=19.40 Mean=20.91 
S.D.= 10.99 S.D.= 7.08 
Dark Mean=15.68 Mean=15.91 
S.D.= 8.48 S.D.= 6.21 
Time to Maximum Overall Mean=24.00 Mean=23.25 
Dilation S.D.= 7.30 S.D.= 6.46 
(minutes} Light Mean=26.25 Mean=24.00 
S.D.= 5.50 S.D.= 5.55 
Medium Mean=21.60 Mean=24.00 
S.D.= 8.10 S.D.= 6.32 
Dark Mean=25.00 Mean=21.00 
S.D.= 7.97 S.D.= 8.27 
DISCUSSION: 
We hypothesized that a substandard dose of a topical mydriatic agent would 
create a pupillary dilation equivalent to that of a larger, standard-sized 
dose. This study found no statistically significant difference in pupillary 
dilation when a topically-administered quantity of the combination of 
hydroxyamphetamine hydrobromide 1% and tropicamide 0.25% was 
administered in a 10 ~-tL versus a 30 ~-tL dosage. When comparing the 
increase in mean pupil area, the increase in mean pupil diameter, and mean 
time to maximum dilation within 30 minutes, we found no statistically 
significant difference between a 1 0 ~-tl and a 30 ~-tl dosage of the mydriatic. 
It is clear that the goal of dilation should be a rapid and maximally-dilated 
pupil.24 Minime1lly-dilated pupils pose a risk of pupillary-block glaucoma 
that is not present with maximally-dilated pupils.5 A pupillary diameter of 
7 mm is usually adequate to permit thorough examination of the fundus, 
including the peripheral retina. 21 Our research found that a 10 ~-tL drop of 
mydriatic did indeed provide a pupillary dilation of '2:.7 mm diameter for 
100% of our subjects within 30 minutes, thus achieving a clinically 
significant dilation in all eyes tested. Our results indicate that a properly-
administered 1 0 ~-tL dose of the combination of hydroxyamphetamine 
hydrobromide 1% and tropicamide 0.25% is equally efficacious for pupillary 
dilation when compared to a 30 ~-tL dose. 
It should be noted that although we only recorded and analyzed the time to 
maximum dilation within the 30 minute time frame, it is possible, and even 
likely, that an even greater pupillary dilation was achieved beyond the 30 
minute window. The PDR for Ophthalmology states that maximum dilation 
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will be achieved within 60 minutes with Paremyd.8 However, we believe it 
is often unrealistic for the patient and doctor to wait longer than 30 
minutes for dilation to occur before proceeding with a dilated fundus 
examination. Therefore, we believe the data we obtained in the 30 minutes 
post-drug instillation should be considered to be more clinically applicable 
than if we had used a one hour time frame. 
The human lacrimal fluid volume in the lower eyelid sac is normally between 
7 and 10 Jll, and can expand momentarily and variably to 30 Jll without 
overflow.13-16 Therefore, a normal tear volume of 7-10 Jll plus a single 30 
Jll drop already exceeds holding capacity. Two drops instilled concurrently 
produce a total volume greater than 67 Jll, severely exceeding maximum 
capacity, thus producing spillage and increased lacrimal drainage. 
The lacrimal fluid is itself normally being turned over at a rate estimated to 
be 16% per minute.16 Blinking will considerably increase the rate at which 
the tear volume (i.e., tears plus eye drops) is drained into the nasolacrimal 
apparatus. Topical application to the lower cul-de-sac, accompanied with 
nasolacrimal occlusion, is the standard method of administering eye drops in 
order to increase bioavailability and therapeutic index; thus, this method 
was utilized for this study.22 Zimmerman eta/. have found that nasolacrimal 
occlusion in conjunction with post-instillation eyelid closure reduces 
systemic absorption of the drug by more than 60%.25 
Once instilled, topical ocular pharmaceutical agents gain access to the 
nasolacrimal drainage system; the loss of drug decreases topical efficacy 
and increases the potential for systemic absorption. In addition, drug 
dilution and loss will increase as drop size increases because instillation of 
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a greater drop volume causes an increased potential for ocular irritation and 
reflex blinking, eliciting reflex lacrimation which dilutes the drug and 
increases the drainage rate to the nasolacrimal canal. An excess of 
tear/drug volume beyond maximum holding capacity of the lower eyelid sac 
will also cause increased nasolacrimal drainage and spillage onto the cheeks 
and eyelashes. 14'19 We did not measure systemic absorption, but it is clear 
that the potential for systemic toxicity may be increased by the large size 
of commercial eye drops.9'10'13'19'26 A small eye drop volume improves 
bioavailability in many ways;13'14'19 it provokes less reflex tearing, causing 
less drug dilution on contact with lacrimal fluid. Reduced tear volume also 
decreases drug loss through lacrimal drainage. Therefore, eye drops 
administered in smaller volumes should achieve a greater tear-film 
concentration and longer contact time, thus improving corneal penetration. 
Application of multiple drops at one time is not recommended. While one 
may initially believe that ocular bioavailability is increased, in reality 
over-capacity spillage and lacrimal washout occur, resulting in increased 
lacrimal drainage, increased systemic uptake, and possible side effects or 
toxicity. 15 If two drugs must be given, it is recommended that they be 
instilled at least five minutes apart so that the first drop can be 
sufficiently diluted and absorbed prior to application of the second drop. 13'27 
It should be noted that we are not recommending mydriatic drops be 
produced in higher concentrations; rather, we are suggesting drug 
manufacturers make the mydriatics available in eyedroppers which produce 
lower volume droplets. Theoretically, the therapeutic index of most topical 
drugs may be improved by increasing drug concentration and decreasing 
volume.14 To maintain patient safety, however, this approach depends on a 
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delivery system capable of insuring that only a single drop is delivered per 
dose; this is currently not possible with commonly-available eyedroppers. 
Ophthalmic solutions and suspensions are generally administered by means 
of a squeeze bottle with an attached dropper tip, and one of the criteria the 
drop size is influenced by is the outer diameter of this dropper tip surface. 
Several eyedroppers with small outer tip diameters have been proposed 
which produce drops smaller than 30 ~1. 11 ' 12 '20 '28 ' 29 In addition to tip 
diameter, drop size is influenced by the density and the dynamic surface 
tension of the solution. Therefore, no standard dropper can be used for all 
solutions or suspensions.14 However, Hurst eta/. claim that dropping angle, 
drug type, and drop number were the only factors influencing drop size; their 
study showed that a reduction in dropping angle of the eyedropper to less 
than 60° from the horizontal provided a smaller drop volume.30 
Without a single-drop delivery system, safety considerations may limit the 
application of the high concentration/small volume approach. For instance, 
delivering a topical mydriatic or cycloplegic drug as a highly concentrated, 
small volume droplet may improve the therapeutic index if only a single drop 
is administered. However, the practitioner or assistant may inadvertently 
instill multiple drops with each delivery, and a highly concentrated drug 
could lead to an increased risk of systemic toxicity. 
It is often believed that eyes with less pigmentation (i.e., lighter irides) 
more readily respond to mydriatics as compared to eyes with more 
pigmentation.31 -33 Opposing that viewpoint, other research claims equal 
mydriasis occurs between light and dark irides.34-38 Our research shows the 
eyes with lighter colored irides generally achieved an overall larger dilation 
as compared to those with darker irides (dosage independent); but within any 
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given irides darkness category, there is no significant statistical difference 
between the dilation of the 1 0 ).ll eyes and the 30 ).ll eyes. This indicates 
that a smaller mydriatic droplet is equally effective as a larger drop 
regardless of iris color. (However, it should be noted that our data using 
irides darkness as an analysis criterion has limited foundation due to the 
small population size tested within each darkness category). 
One other expected benefit to the patient for the utilization of smaller 
ophthalmic droplets is greater comfort during instillation. Many of our 
subjects were not aware of the 1 0 ).ll droplet being instilled, yet they 
usually felt the larger 30 ).ll drop. This too was noted by other researches 
during similar investigations. 11 '12 
This and other studies9 -12' 17'18 '26 make it clear and plausible that mydriatic 
drop volumes well below those currently utilized by standard delivery 
systems can and should be used to dilate the pupils with adequate clinical 
efficacy in a timely manner. This, in turn, will decrease systemic 
absorption, thereby reducing the inherent risks of mydriatic-induced side 
effects. 
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